Technology & innovation

We are developing a new, highly innovative injectable medical device designed to regenerate natural soft tissue.

This product is designed to address volume loss in the mid-face region — offering an immediate lift followed by the formation of the body’s own functional adipose tissue. By supporting the body’s own regenerative processes, it aims to deliver durable results. This innovation is positioned to set a new standard in aesthetic medicine, offering a sustainable alternative to synthetic fillers and autologous treatments. Current fillers and invasive autologous methods can not deliver similar benefits in a scalable way.

What makes this truly exciting is that this medical device will leverage our Tience® technology — already in commercial use in the Nordics and supported by clinical research and real-world data. Now, we’re taking that foundation and applying it to a new indication with global potential.

RESEARCH

We have achieved proof-of-concept and demonstrated promising results confirming the mode of action in our pre-clinical development.

Cutting edge research paves the way for advancing our product development plan, targeting CE-marking and FDA-approval.

WHY IT MATTERS

Current filler treatments fall into two unsatisfactory categories: synthetic fillers, which are temporary, nonregenerative, and increasingly linked to safety and overuse concerns; and autologous therapies, such as fat transfers and cell therapies, which offer biological benefits but are invasive, expensive, and difficult to scale. Current autologous methods, such as platelet-rich plasma (PRP) therapy, nanofat and microfat grafting often require complex and invasive procedures. Patients and physicians are increasingly demanding natural, ready-to-use alternatives — but there is no scalable regenerative injectable for mid-face volumization on the market.

OVER 20% OF GLOBAL FILLER USE IS IN THE CHEEK VOLUMIZATION

It is an increasingly interesting area as non-surgical approaches and biostimulation gain popularity over risky surgical procedures. The mid-face is a top indication for non-surgical facelifts, as the customers often suffer from lipoatrophy due to aging or disease.

‍

• Proof of concept achieved in current pre-clinical development and clinical case reports

• Ongoing pre-clinical studies support our pipeline development

• Tience® technology as a component is derisking development as its efficacy and safety have been proven in clinical trials and on the market.

‍

Tience technology and leveraging it in medical devices and its production process are covered by international patents.